Treatment-emergent candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with Ixekizumab: an integrated safety analysis of 25 clinical studies

This is the authors' abstract. We don't add key points for this paper.

This safety analysis investigates treatment-emergent mucosal/cutaneous Candida infections in patients treated with ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, across the approved indications: psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).